MarketBeat
12 Jul 2026, 21:02 UTC · 2h ago
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
12 Jul 2026, 21:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Dr. Reddy's will miss expected semaglutide sales for July, August, September, and October due to a scale-up impurity issue. — Direct loss of revenue for four consecutive months on a high-demand product (semaglutide) creates a significant short-term financial headwind.
-0.70The company confirmed that the impurity issue did not affect products already in the market and there are no recall concerns for semaglutide. — Prevents a much worse scenario involving mass recalls, liability, and systemic regulatory sanctions.
+0.40Commercial supply of semaglutide injections is expected to restart in late October or early November, pending successful validation batches. — Provides a timeline for recovery but acknowledges a risk of further delays if validation fails again.
-0.30Continue reading
6 related stories
Top 1 mover · tap to explore
The manufacturing issue does not affect oral semaglutide tablets or existing global regulatory filings. — Limits the impact to a single product format and preserves the company's regulatory standing.
+0.20A backup API supplier is being qualified but will not be operational for approximately one year. — Indicates long-term risk mitigation but offers no immediate relief for the current supply gap.
-0.10Which stocks this story touches
The company is facing a scale-up issue with its semaglutide injection leading to temporary supply delays and missed sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Fox Business
3h ago
